1. Introduction {#sec1-jcm-09-02608}
===============

Optic neuritis (ON) is an acute inflammatory optic neuropathy that may be associated with dramatic visual loss and an important decrease in quality of life in absence of an adequate treatment. Multiple Sclerosis (MS) ON, the most common form of presentation, is characterized by unilateral acute retroocular pain and visual loss, more commonly observed in Caucasian women between 18 and 50 years \[[@B1-jcm-09-02608]\]. Visual acuity (VA) in patients with MS-ON usually improves within a few months even without treatment \[[@B2-jcm-09-02608],[@B3-jcm-09-02608],[@B4-jcm-09-02608]\]. Non-MS ON is less frequent and can be an isolated disorder or related to infections and immune-mediated diseases such as Neuromyelitis Optica (NMO) or other systemic diseases \[[@B5-jcm-09-02608]\]. Non-MS ON may have atypical features such as male gender, age less than 18 or greater than 50 years, absence of pain and bilateral presentation \[[@B5-jcm-09-02608]\]. In non-MS ON, a chronic progressive disease is more common. Flare-ups are frequent, leading often to visual loss \[[@B3-jcm-09-02608],[@B6-jcm-09-02608]\]. If not promptly treated, the visual outcome can be devastating, causing a severe visual loss, and even with adequate treatment, many patients may worsen over months \[[@B7-jcm-09-02608],[@B8-jcm-09-02608],[@B9-jcm-09-02608],[@B10-jcm-09-02608]\].

Therapy has been mostly focused on MS-ON. According to the Optic Neuritis Treatment Trial \[[@B2-jcm-09-02608]\], in patients with MS or isolated ON, intravenous (i.v.) high-dose glucocorticoids followed by oral prednisolone may accelerate the visual recovery. Nevertheless, there is not a significant improvement of VA at 6 months and 1 year compared to placebo. The most recent Cochrane Review identified six randomized controlled trials with a total of 750 participants. Five trials (*n* = 633) only analyzed MS or isolated ON. It concluded that there is still no definitive evidence that i.v. glucocorticoids improve visual outcomes after 6 months of treatment \[[@B11-jcm-09-02608]\].

Non-MS ON treatment has been less frequently assessed. Glucocorticoids, plasmapheresis and intravenous immunoglobulins may be effective in acute attacks, particularly in NMO \[[@B12-jcm-09-02608],[@B13-jcm-09-02608],[@B14-jcm-09-02608],[@B15-jcm-09-02608]\]. Three recent clinical trials have analyzed the use of satralizumab, eculizumab and inebilizumab in NMO \[[@B16-jcm-09-02608],[@B17-jcm-09-02608],[@B18-jcm-09-02608]\]. All three have demonstrated a reduction of risk of NMO attack compared to placebo. Conventional immunosuppressive therapies have demonstrated clinical benefits for reducing relapses \[[@B6-jcm-09-02608]\], but biologic agents have been rarely used. Thus, rituximab (RTX), an anti-CD20 monoclonal antibody, tocilizumab (TCZ), an IL-6 monoclonal antibody \[[@B12-jcm-09-02608],[@B19-jcm-09-02608],[@B20-jcm-09-02608],[@B21-jcm-09-02608],[@B22-jcm-09-02608]\], and anti-TNFα therapy, especially adalimumab (ADA) and infliximab (IFX), have been only used in some refractory cases \[[@B23-jcm-09-02608],[@B24-jcm-09-02608],[@B25-jcm-09-02608],[@B26-jcm-09-02608],[@B27-jcm-09-02608]\].

Taking into account all these considerations, this study aimed to assess the efficacy and safety of biologic therapy in refractory non-MS ON, both isolated and associated with immune-mediated inflammatory diseases.

2. Experimental Section {#sec2-jcm-09-02608}
=======================

2.1. Design and Enrollment Criteria {#sec2dot1-jcm-09-02608}
-----------------------------------

We performed an observational open-label multicenter study that included 19 patients diagnosed with non-MS ON refractory to systemic glucocorticoids and at least one conventional immunosuppressive drug.

Patients were diagnosed with non-MS ON at the Ophthalmology, Neurology and Rheumatology Units of eleven different referral Spanish Hospitals. Since biologic therapy is an off-label indication for ON, written informed consent was requested and obtained from all the patients. The study was approved by the Clinical Research Ethics Committee (ethical approval code: 2020.010).

Diagnosis of ON was based on clinical features, ophthalmologic examination, high-definition optical coherence tomography (OCT), magnetic resonance imaging (MRI) and cerebrospinal fluid analysis (CSF). The presence of subacute vision loss in adults, along with a relative afferent papillary defect (RAPD) was required for diagnosis \[[@B2-jcm-09-02608],[@B3-jcm-09-02608],[@B4-jcm-09-02608],[@B5-jcm-09-02608]\]. In addition, MRI findings such either T1-weighted gadolinium enhancement of the optic nerve, or T2-weighted optic nerve hyperintensity were needed for diagnosis \[[@B28-jcm-09-02608],[@B29-jcm-09-02608]\]. Aquaporin-4 water channels -IgG and Myelin Oligodendrocyte Glycoprotein -IgG were assessed in all patients. Both unilateral and bilateral cases of ON were included in the diagnosis.

Inclusion criteria were as follows: (a) non-MS ON, (b) lack of response to previous treatment with a high dose of systemic glucocorticoids defined as more than 7.5 mg/day for more than 3 months and (c) to at least one conventional immunosuppressive drug at its standard doses.

MS was excluded by the McDonald's criteria that were based on clinical, imaging and laboratory parameters \[[@B30-jcm-09-02608]\].

As indicated by the Spanish Biologic Treatment Administration National Recommendations, the presence of infectious diseases had to be ruled out before starting the biologic treatment. To exclude latent tuberculosis, a tuberculin skin testing (PPD) and/or an interferon assay (quantiFERON) and chest radiography were performed. In positive cases, prophylaxis with isoniazid was initiated for at least 4 weeks before using the biologic treatment and was maintained for 9 months. The presence of malignancies was excluded in all patients \[[@B31-jcm-09-02608],[@B32-jcm-09-02608],[@B33-jcm-09-02608],[@B34-jcm-09-02608],[@B35-jcm-09-02608],[@B36-jcm-09-02608],[@B37-jcm-09-02608],[@B38-jcm-09-02608],[@B39-jcm-09-02608]\].

According to current guidelines, avoiding the use of anti-TNFα drugs is recommended in patients with a history or familiar occurrence of demyelinating diseases \[[@B4-jcm-09-02608],[@B40-jcm-09-02608]\]. Besides, a relatively common anti-TNFα Adverse Event (AE) is ON \[[@B41-jcm-09-02608],[@B42-jcm-09-02608]\]. Thus, anti-TNFα therapy was avoided in NMO (demyelinating disease).

2.2. Outcome Variables {#sec2dot2-jcm-09-02608}
----------------------

The outcome variables were the efficacy and the safety of biologic therapy. The main outcomes of efficacy were best-corrected visual acuity (BCVA), retinal nerve fiber layer (RNFL), and macular thickness (MT). Secondary outcomes were remission, number of relapses and sparing effect of glucocorticoids. To determine safety, AE were evaluated.

BCVA was estimated by the logMAR chart. The optic nerve was evaluated measuring with an OCT the loss of retinal nerve fibers with RNFL analysis. The loss of retinal nerve fibers associated with optic atrophy in patients with optic neuropathies can easily be visualized and quantified by OCT measuring the peripapillary RNFL \[[@B43-jcm-09-02608]\]. The RNFL thickness was measured using the optic disc cube protocol of the Fourier Cirrus HD-OCT (Carl Zeiss Meditec Inc., Dublin, CA, USA) software, version 6.0. This protocol generates a cube of data through a 6-mm square grid by acquiring a series of 200 horizontal scan lines, each composed of 200 A-scans. The RNFL thickness at each pixel is measured and an RNFL thickness map is generated. RNFL thickness quantification is a good measure of axonal integrity associated with VA. It can predict the degree of visual recovery in acute cases of non-MS ON \[[@B44-jcm-09-02608],[@B45-jcm-09-02608]\].

Similarly, macular edema has been related to non-MS ON prognosis \[[@B46-jcm-09-02608]\]. The macular cube 512 × 128 scan was used to obtain MT; this protocol performs 512 horizontal A-scans and 128 vertical B-scan lines within a 6 × 6 mm cube of acquired signal data centered on the fovea. It has been assessed evaluating six areas of the macular cube (superior, superonasal, inferonasal, inferior, inferotemporal and superotemporal sectors) \[[@B46-jcm-09-02608]\]. Besides, MRI was performed to determine optic nerve inflammatory changes and to rule out structural lesions or other causes of ON \[[@B47-jcm-09-02608],[@B48-jcm-09-02608],[@B49-jcm-09-02608],[@B50-jcm-09-02608]\].

Remission was defined as the absence of ON symptoms and signs that lasted longer than 24 h, with or without an associated new lesion on MRI with gadolinium contrast agents for at least 3 months \[[@B51-jcm-09-02608],[@B52-jcm-09-02608]\]. The remission status was classified as complete when there was full recovery of visual outcomes, partial recovery when there was incomplete recovery and no remission when there was no improvement at all \[[@B53-jcm-09-02608]\]. Relapses were defined as new ON symptoms and signs that lasted longer than 24 h, with or without an associated new lesion on MRI with gadolinium contrast agents \[[@B52-jcm-09-02608]\]. AE related to biologic treatment were evaluated and recorded at follow-up.

2.3. Data Collection and Statistical Analysis {#sec2dot3-jcm-09-02608}
---------------------------------------------

These outcome variables were recorded in each center according to a follow-up protocol agreed beforehand. Information was stored in a computerized database, and to minimize entry error, all data were double-checked.

Results are expressed as mean ± standard deviation (SD) for the variables with a normal distribution or as median and interquartile range (25th--75th interquartile range (IQR)) for those not normally distributed. Continuous variables were compared with the 2-tailed Student t-test or the Mann--Whitney U-test, as appropriate. The chi-square test or the Fisher exact test was used for the dichotomous variables. The outcome variables were assessed and compared between baseline (at biologic therapy initiation), 1 week, 1 month, 3 months, 6 months and 1 year separately in each outcome, and Wilcoxon signed-rank test was used to assess continuous variables.

3. Results {#sec3-jcm-09-02608}
==========

3.1. Demographic and Clinical Features at Baseline {#sec3dot1-jcm-09-02608}
--------------------------------------------------

We studied 19 patients (11 women/ 8 men) with non-MS ON refractory to systemic glucocorticoids and at least one conventional immunosuppressive drug. The mean age was 34.8 ± 13.9 years. The underlying diseases were idiopathic ON (*n* = 6), Bechet's disease (*n* = 5), NMO (*n* = 3), systemic lupus erythematosus (SLE) (*n* = 2), sarcoidosis (*n* = 1), relapsing polychondritis (*n* = 1), and myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated vasculitis (*n* = 1). Non-MS ON was unilateral (*n* = 10) and bilateral (*n* = 9). The main demographic and clinical data are summarized in [Table 1](#jcm-09-02608-t001){ref-type="table"}.

Before biologic therapy initiation, all patients had received oral glucocorticoids (mean Maximum prednisone dose, 53.7 ± 17.7 mg/day). In 16 cases, i.v. pulses of Methylprednisolone (MP) (mean ± SD dose 3.3 ± 1.5 g) were used before oral glucocorticoids. The conventional immunosuppressive drugs previously used and doses were azathioprine (AZA) (*n* = 8; 100--250 mg/p.o./day), methotrexate (MTX) (*n* = 7; 15--25 mg/s.c. or p.o./week), mycophenolate mofetil (MMF) (*n* = 5; 760--2000 mg/p.o./day), cyclophosphamide (CPM) (*n* = 4; 9 mg/kg/i.v./weekly), hydroxychloroquine (HCQ) (*n* = 2; 200--400 mg/p.o./day), cyclosporine A (CyA) (*n* = 2; 250--300 mg/p.o./day) and leflunomide (LFN) (*n* = 1; 20 mg/p.o/day). ([Figure 1](#jcm-09-02608-f001){ref-type="fig"}).

At biologic therapy initiation, MRI with gadolinium contrast agents was performed in all patients with the following results: normal (*n* = 8), ocular enhancement (chiasma (*n* = 1), choroidal bilateral (*n* = 1), periorbital bilateral (*n* = 1)), spinal cord enhancement (transverse myelitis (*n* = 2); C2-D3 (*n* = 1); C1-T1 (*n* = 1); D5-D7 (*n* = 1)), and cerebral enhancement (frontal subcortical bilateral (*n* = 1), supratentorial (*n* = 1)). CSF fluid analysis was only performed in 3 patients obtaining normal results in all of them.

3.2. Biologic Therapy and Efficacy {#sec3dot2-jcm-09-02608}
----------------------------------

Biologic agents used were RTX (*n* = 6; two i.v. doses of 1 g/every 2 weeks and then every 6 months), ADA (*n* = 6; 40 mg/sc/1-2 week), IFX (*n* = 5; 5 mg/kg/i.v. at 0, 2 and 6 weeks and then every 8 weeks) and TCZ (*n* = 4; 2 as first and 2 as second biologic therapy; 8 mg/kg/i.v. 2--4 weeks). A second immunosuppressive drug was used simultaneously in 11 patients: MTX (*n* = 11), AZA (*n* = 2), MMF (*n* = 1) and HCQ (*n* = 1). In addition, all patients received oral prednisone (median (IQR) maximum dose at baseline of 40 (10--61.5) mg/day).

Thus, after one year of biologic therapy, mean ± SD BCVA improved from 0.63 ± 0.34 logMAR to 0.84 ± 0.29 logMAR (*p* = 0.03). Similarly, a significant improvement in optic nerve inflammation was observed since mean ± SD RNFL OCT increased from 183.4 ± 139.6 to 190.5 ± 175.4 µm (*p* = 0.02). Mean ± SD MT decreased from 369.6 ± 137.4 to 270.7 ± 23.2 μm (*p* = 0.03) ([Figure 2](#jcm-09-02608-f002){ref-type="fig"}). A 10.5% (7.1% of eyes) of patients experience a loss in BCVA.

After a mean ± SD follow-up of 35.3 ± 25.1 months, 15 patients (78.9%) achieved ocular remission \[[@B51-jcm-09-02608],[@B52-jcm-09-02608]\]. They were on ADA (*n* = 6, 83.3%), RTX (*n* = 6, 66.6%), IFX (*n* = 5, 60%) and TCZ (*n* = 4, 100%). Only one relapse was described, at 3 months of RTX therapy in one patient.

Likewise, a decrease in the median (IQR) prednisone dose was also achieved (40 (10--61.5) mg/day at baseline vs. 2.5 (0--5) mg/day at one year of follow-up; *p* = 0.001) ([Figure 3](#jcm-09-02608-f003){ref-type="fig"}). Before the initiation of biological therapy, all patients required an oral prednisone dose of more than 7.5 mg/day after 3 months. After 3 months of biological therapy, 43.7% of patients required an oral prednisone dose of more than 7.5 mg/day. The biological therapies that required high doses of corticosteroids for more than three months were IFX (*n* = 2), ADA (*n* = 1), RTX (*n* = 1).

Anti-TNFα drugs (ADA, IFX, *n* = 11) were compared with non-anti-TNFα (RTX, TCZ, *n* = 10) agents ([Table 2](#jcm-09-02608-t002){ref-type="table"}). The underlying diseases were different in both groups. In Bechet's Disease and sarcoidosis, anti-TNFα were used more frequently, and in NMO and SLE, non-anti-TNFα agents were the most frequently prescribed. At one-month, a greater improvement in BCVA was observed with anti-TNFα drugs (*p* = 0.048) while a greater change from baseline in RNFL OCT was observed with non-anti-TNFα drugs (*p* = 0.007). In any case, at one-year of biologic therapy, improvement in BCVA and RNFL OCT was similar in both groups.

3.3. Safety of Biologic Therapy {#sec3dot3-jcm-09-02608}
-------------------------------

Severe AEs were observed in 2 patients (10.5%), a 30-year-old woman who suffered a severe infusion-related reaction to RTX and a 28-year-old man who had severe nausea and vomiting while on ADA.

IFX was withdrawn in 2 patients (10.5%) due to ongoing active neuritis. Both developed anti-drug antibodies and tachyphylaxis after 36 and 5 months of treatment. They were switched to TCZ achieving complete remission.

4. Discussion {#sec4-jcm-09-02608}
=============

In this study, biologic therapy with both anti-TNFα (ADA, IFX) and non-anti-TNFα (RTX, TCZ) drugs was useful in patients with non-MS ON refractory to systemic glucocorticoids and at least one conventional immunosuppressive drug.

About 20% of patients with non-MS ON are refractory to conventional immunosuppressive drugs \[[@B54-jcm-09-02608]\]. Some studies have analyzed the efficacy of biologic therapy in these cases achieving complete remission in a large number of patients. The use of RTX in NMO has been well-established. Recently, a metanalysis that included 26 studies and 577 participants analyzing the effectiveness of RTX in NMO was conducted \[[@B20-jcm-09-02608]\]. In this study, 62.9% participants reached complete remission. Similarly, in a clinical trial conducted with 7 patients with NMO refractory to treatment, a monthly injection of TCZ was given to all patients. Complete remission was reached in 71.4% of patients. There is less information on anti-TNFα effectiveness. A recent study analyzed the use of IFX in 11 patients with ocular Behçet's disease. Six patients had ON. A total of 5 patients achieved partial remission, and 1 patient achieved complete remission after a mean ± SD follow-up of 12.3 ± 5.7 years \[[@B25-jcm-09-02608]\]. Two single cases of neurosarcoidosis refractory to treatment achieved partial remission with the use of IFX \[[@B55-jcm-09-02608],[@B56-jcm-09-02608]\]. Recently, other biologic therapies such as satralizumab, eculizumab and inebilizumab have been tested in NMO in three recent clinical trials with promising results \[[@B16-jcm-09-02608],[@B17-jcm-09-02608],[@B18-jcm-09-02608]\]. These new clinical trials underline the necessity of new treatment options for non-MS ON and the importance of biological therapy in management of this disease.

In our study, 15 out of 19 patients were relapse-free, and the treatment response rate was 78.9%. The study showed the efficacy of biologic therapy on refractory non-MS ON and compared the efficacy and safety of four different biologic agents. Patients with idiopathic ON were treated with either anti-TNFα or non-anti TNFα drugs. In contrast, patients with an underlying disease were treated with anti-TNFα or non-anti TNFα agents, based on the underlying disease's latest treatment guidelines and evidence-based clinical information \[[@B57-jcm-09-02608],[@B58-jcm-09-02608],[@B59-jcm-09-02608],[@B60-jcm-09-02608],[@B61-jcm-09-02608],[@B62-jcm-09-02608]\]. BCVA and RNFL OCT results were different in patients treated with non-anti-TNFα compared to patients treated with anti-TNFα agents in early stages of the study. The reason is unknown. However, it seems that initially a release of large amounts of TNF-α can decrease visual acuity while a high CD19+B cell response and immunoglobulin synthesis could reduce RFNL thickness \[[@B63-jcm-09-02608],[@B64-jcm-09-02608]\]. This initial difference in pathogenesis could maybe explain the disparity of these results.

Biologic therapy was well tolerated in our series. However, two severe AEs related to the use of RTX were observed. Severe AE rate in other studies has been similar to ours: TCZ (1--8%) \[[@B65-jcm-09-02608]\], ADA (5%) \[[@B66-jcm-09-02608]\], IFX (4%) \[[@B67-jcm-09-02608]\], RTX (1--4%) \[[@B68-jcm-09-02608]\]. The slightly higher AEs rate in this study may relate to the smaller sample sizes than in other studies.

The present study has several limitations which affect the generalization of the results. First, the study population was only from Spain. Second, there is an important lack of data in practically every variable. Third, the variability in time of follow-up makes results hard to compare and correlate. A larger scale study should be performed to identify more subtle associations.

In conclusion, the present study suggests that biologic therapy may be effective in patients with non-MS ON refractory to systemic glucocorticoids and conventional immunosuppressive drugs. Further controlled prospective studies with a larger sample are needed to confirm our results. However, patient recruitment might be difficult, as non-MS ON refractory to systemic glucocorticoids and immunosuppressive drugs are a heterogeneous and rare condition. The use of a multicenter international randomized clinical trial would maybe help to overcome not only this challenge but also the challenge that only certain biologics are currently licensed for certain diseases depending on the geographical area, and it would help decrease the cost of these drugs. In the meantime, clinical series are certainly helpful to improve our understanding and management of this disorder.
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![Flow-chart of biologic therapy in refractory non-Multiple Sclerosis optic neuritis. Abbreviations: ADA: Adalimumab, IFX: Infliximab; IS: Immunosuppressive, RTX: Rituximab; TCZ: Tocilizumab.](jcm-09-02608-g001){#jcm-09-02608-f001}

![Improvement in (**a**) Best Corrected Visual Acuity (BCVA) and (**b**) Optical Coherence Tomography (OCT) measurements. Abbreviations: BCVA: Best Corrected Visual Acuity; MT: Macular Thickness, OCT: Optical Coherence Tomography; RNFL: Retinal Nerve Fiber Layer. \* *p* \< 0.05 compared with basal data.](jcm-09-02608-g002){#jcm-09-02608-f002}

![Glucocorticoid sparing effect of biologic therapy in refractory non-Multiple Sclerosis Optic Neuritis. \* *p* \< 0.05 compared with basal data.](jcm-09-02608-g003){#jcm-09-02608-f003}

jcm-09-02608-t001_Table 1

###### 

Main features of 19 patients with refractory non-Multiple Sclerosis Optic Neuritis treated with biologic therapy.

  Case   Gender/Age   Underlying Disease         Cumulative i.v. Steroids Dose (g over 1--3 days)   Max. Oral Prednisone Dose (mg/day)   Conventional IS Drugs   Max. AZA Dose (mg/p.o./day)   Max. MTX Dose (mg/s.c. or p.o./week)   Max. MMF Dose (mg/p.o./day)   Biologic Therapy
  ------ ------------ -------------------------- -------------------------------------------------- ------------------------------------ ----------------------- ----------------------------- -------------------------------------- ----------------------------- ------------------
  1      F/29         Idiopathic                 4                                                  60                                   AZA                     150                                                                                                TCZ
  2      F/26         Idiopathic                 5.5                                                30                                   AZA                     100                                                                                                TCZ
  3      F/13         Idiopathic                 \-                                                 10                                   MTX                                                   15                                                                   ADA
  4      F/25         Idiopathic                 3                                                  60                                   MTX                                                   25                                                                   IFX, TCZ
  5      F/24         Idiopathic                 0.5                                                60                                   MTX, AZA                100                           22.5                                                                 ADA
  6      M/14         Idiopathic                 \-                                                 10                                   MTX                                                   25                                                                   ADA
  7      M/21         Behçet's disease           0.5                                                60                                   MTX, AZA                150                           25                                                                   ADA
  8      M/25         Behçet's disease           3                                                  60                                   MTX, CyA                                              20                                                                   ADA
  9      M/39         Behçet's disease           \-                                                 80                                   MMF                                                                                          1000                          IFX
  10     M/40         Behçet's disease           \-                                                 80                                   MMF                                                                                          2000                          IFX
  11     M/37         Behçet's disease           \-                                                 60                                   CyA                                                                                                                        IFX
  12     F/68         NMO                        2.5                                                30                                   CPM, AZA                100                                                                                                RTX
  13     F/41         NMO                        3                                                  60                                   CPM                                                                                                                        RTX
  14     M/43         NMO                        5                                                  60                                   AZA                     250                                                                                                RTX
  15     F/56         SLE                        4.5                                                60                                   HCQ                                                                                                                        RTX
  16     F/47         SLE                        5                                                  60                                   HCQ, MMF                                                                                     750                           RTX
  17     F/43         Relapsing polychondritis   3                                                  60                                   MTX, CPM                                              15                                                                   IFX, TCZ
  18     M/41         Sarcoidosis                3                                                  40                                   AZA                     100                                                                                                ADA
  19     F/30         Vasculitis ANCA+           3                                                  60                                   AZA, MMF, LFM, CPM      100                                                                  1000                          RTX

Abbreviations: ADA: Adalimumab, ANCA: Anti-Neutrophil Cytoplasmic Antibody, AZA: Azathioprine, CPM: Cyclophosphamide, CyA: Cyclosporine A, F: Female, HCQ: Hydroxychloroquine, IS: Immunosuppressive, IFX: Infliximab, i.v. intravenous, IS: Immunosuppressant, M: Male, Max.: Maximum, MMF: Mycophenolate Mofetil, MTX: Methotrexate, NMO: Neuromyelitis Optica RTX: Rituximab, SLE: Systemic Lupus Erythematosus, TCZ: Tocilizumab. Not all patients were available for the planned follow-up at the specified interval. In concrete, there was a loss to follow-up 5 patients after 3 and 6 months. A total of 6 patients were loss to follow-up after 1 year.

jcm-09-02608-t002_Table 2

###### 

Comparison of patients treated with anti-TNFα and with non-Anti-TNFα.

  -----------------------------------------------------------------------------------------
                                     Anti-TNFα                       Non-Anti-TNFα
  ---------------------------------- ------------------------------- ----------------------
  *n*                                11                              8

  Sex, *male/female*                 7M/4F                           1M/7F

  Mean age, (*SD*)                   29.3 (11.0)                     42.5 (14.5)

                                                                     

  Underlying disease, (*n*)          Behçet's disease (5)\           NMO (3)\
                                     Idiopathic (4)\                 Idiopathic (2)\
                                     Relapsing polychondritis (1)\   SLE (2)\
                                     Sarcoidosis (1)\                Vasculitis ANCA+ (1)

                                                                     

  Conventional IS, (*n*)             MTX (7)\                        AZA (5)\
                                     AZA (3)\                        CPM (3)\
                                     MMF (2)\                        MMF (2)\
                                     CyA (1)\                        HCQ (2)\
                                     CPM (1)                         LFM (1)

                                                                     

  Second biologic therapy, (*n*)     TCZ (2)                         \-

  Mean follow up in months, (*SD*)   32.6 (20.1)                     38.6 (31.4)

  Remission, *n* (*%*)               8 (72.7)                        5 (62.5)
  -----------------------------------------------------------------------------------------

Abbreviations: ADA: Adalimumab, ANCA: Anti-Neutrophil Cytoplasmic Antibody, AZA: Azathioprine, CPM: Cyclophosphamide, CyA: Cyclosporine A, F: Female, HCQ: Hydroxychloroquine, IFX: Infliximab, IS: Immunosuppressive drug, M: Male, MMF: Mycophenolate Mofetil, MTX: Methotrexate, NMO: Neuromyelitis Optica RTX: Rituximab, SLE: Systemic Lupus Erythematosus, TCZ: Tocilizumab.
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